Rabacfosadine
 | |
| Clinical data | |
|---|---|
| Trade names | Tanovea |
| Other names | GS-9219 |
| AHFS/Drugs.com | Veterinary Use |
| License data | |
| Routes of administration | Intravenous |
| ATCvet code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C11H35N8O6P |
| Molar mass | 406.425 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Rabacfosadine, sold under the brand name Tanovea, is a guanine nucleotide analog used for the treatment of lymphoma in dogs.[1] It was developed by Gilead Sciences as GS-9219.[2]
The active form of rabacfosadine is a chain-terminating inhibitor of the major deoxyribonucleic acid (DNA) polymerases. In vitro studies have demonstrated that rabacfosadine inhibits DNA synthesis, resulting in S phase arrest and induction of apoptosis.[3] It also inhibits the proliferation of lymphocytes in dogs with naturally occurring lymphoma.[4]
Rabacfosadine was granted conditional approval by the US Food and Drug Administration (FDA) in December 2016,[5] and became the first medication to receive full approval for the treatment of canine lymphoma in July 2021.[6]
Veterinary uses[edit]
In July 2021, the U.S. Food and Drug Administration (FDA) approved Tanovea to treat lymphoma in dogs.[6] Lymphoma, also called lymphosarcoma, is a type of cancer that can affect many species, including dogs.[6] Rabacfosadine is the first conditionally approved new animal drug for dogs to achieve the FDA's full approval.[6]
Adverse effects[edit]
Common side effects of rabacfosadine are decreased white blood cell count, diarrhea, vomiting, decreased appetite or loss of appetite, weight loss, decreased activity level, and skin problems. Other side effects may occur.[5]
References[edit]
- ^ a b "Tanovea- rabacfosadine succinate injection, powder, for solution". DailyMed. 17 January 2023. Retrieved 1 July 2024.
- ^ De Clercq E (August 2018). "Tanovea for the treatment of lymphoma in dogs". Biochemical Pharmacology. 154: 265–269. doi:10.1016/j.bcp.2018.05.010. PMID 29778492.
- ^ Reiser H, Wang J, Chong L, Watkins WJ, Ray AS, Shibata R, et al. (May 2008). "GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma". Clinical Cancer Research. 14 (9): 2824–32. doi:10.1158/1078-0432.CCR-07-2061. PMID 18451250.
- ^ Lawrence J, Vanderhoek M, Barbee D, Jeraj R, Tumas DB, Vail DM (2009). "Use of 3'-deoxy-3'-[18F]fluorothymidine PET/CT for evaluating response to cytotoxic chemotherapy in dogs with non-Hodgkin's lymphoma". Veterinary Radiology & Ultrasound. 50 (6): 660–8. doi:10.1111/j.1740-8261.2009.01612.x. PMID 19999354.
- ^ a b "FDA Conditionally Approves Tanovea-CA1, the first New Animal Drug for Treating Lymphoma in Dogs". U.S. Food and Drug Administration (FDA) (Press release). 3 January 2017. Archived from the original on 1 July 2017.
- ^ a b c d "FDA Grants First Full Approval for Treatment of Lymphoma in Dogs". U.S. Food and Drug Administration (FDA) (Press release). 15 July 2021. Retrieved 27 July 2021.
This article incorporates text from this source, which is in the public domain.
